article thumbnail

Petrie-Flom Welcomes 2023-2024 Student Fellows

Bill Of Health

These five students are a fantastic cohort of health law policy, biotechnology, and bioethics scholars who join us from Harvard Law School. At the law school, Adithi is interested in examining how emerging biotechnologies in regenerative medicine intersect with patient privacy and other ownership rights.

article thumbnail

Why We Should Care About the Move from Saliva to Living Cells in Precision Medicine

Bill Of Health

Regenerative medical technologies use cell- and tissue-based methods to recapitulate, bioengineer, and reprogram human tissue, making a whole suite of sci-fi-sounding technologies an ever-closer reality. It seems, in the near term, that the “who” would probably be a venture-backed biotechnology company — a corporate actor.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Protecting the Consumer at the Heart of DTC Precision Medicine

Bill Of Health

The HIPAA Problem The privatization of next-generation medical technologies, especially in regenerative and precision medicine, further muddies the data-protection waters. The innovation-security tradeoff is a familiar trope in biotechnology, but the main character of the direct-to-consumer tissue-based service story is less so.

article thumbnail

Petrie-Flom Welcomes 2022-2023 Student Fellows

Bill Of Health

These five students are a fantastic cohort of health law policy, biotechnology, and bioethics scholars who join us from across Harvard. Her research currently focuses on the interplay between intellectual property, transfer of technology, and financing to further access to medical technologies.

article thumbnail

Governing Health Data for Research, Development, and Innovation: The Missteps of the European Health Data Space Proposal

Bill Of Health

Is research in the interest of the public domain an activity exclusively developed by academic or healthcare entities, or can it be carried out by industry (pharmaceutical, biotechnology, technology companies, medical technology industries, and insurance providers)? If so, how?

article thumbnail

AI in Digital Health: Autonomy, Governance, and Privacy

Bill Of Health

Trust and Design : Looking closely at data protection issues with a particular emphasis on questions of consent and trust in the context of the new data that is created by medical technologies.

article thumbnail

Will NIH Learn from Myriad when Settling Its mRNA Inventorship Dispute with Moderna?

Bill Of Health

Failing to do so would be a missed opportunity for the public sector to have a say in the distribution and pricing of this critical medical technology. The NIH, which funded much of Moderna’s research on the COVID-19 vaccine, should be assertive in exerting control over the results of this taxpayer-funded research. The Patent Dispute.